Estamos no ar no ! Saiba mais

LivaNova

LIVN

Valor de mercado US$ 4,27 bi

77,58 USD

-0,92

1,17%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

77,58

0,00

0%

1 dia

-1,17%

5 dias

1,92%

1 mês

-1,18%

3 meses

-5,15%

6 meses

19,34%

No acumulado do ano

27,94%

1 ano

43,96%

5 anos

-5,82%

10 anos

37,02%

Sobre: UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Funcionários: 3.300

Saúde Dispositivos médicos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 23,1%

Neutro 69,2%

Negativo 7,7%

LivaNova to Announce Third-Quarter 2026 Results

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the call.The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the.

LivaNova to Announce Third-Quarter 2026 Results

LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

The Motley Fool

LivaNova Director Sells 1,650 Shares for $131,500

The sale was valued at approximately $131,500. The shares traded were equal to 17% of the director's equity stake held directly before the filing.

LivaNova Director Sells 1,650 Shares for $131,500

LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare conferences in New York City: Morgan Stanley 24th Annual Global Healthcare Conference on Mon., Sept. 14, from 11:30 a.m.-12:05 p.m. EDT Baird 2026 Global Healthcare Conference on Tues., Sept. 15, from 11:25-11:55 a.m. EDT Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial.

LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

Artisan International Small-Mid Fund Q2 2026 Portfolio Review

Artisan International Small-Mid Fund portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2. On an individual company basis, NICE, Landis+Gyr and DBV Technologies were the largest Q2 detractors. Our top contributors for the quarter were Rohm, LivaNova and Glanbia.

Artisan International Small-Mid Fund Q2 2026 Portfolio Review

Zacks Investment Research

LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised

LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.

LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

LivaNova Q2 Earnings Call Highlights

LivaNova NASDAQ: LIVN reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation and IT infrastructure.

LivaNova Q2 Earnings Call Highlights

Zacks Investment Research

LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research

LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?

LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™